| Literature DB >> 26813506 |
Yuko Iwashita1, Yu Iwashita1, Takafumi Ito2, Takashi Shigematsu1.
Abstract
CKD is a common disease that is estimated to develop one in eight persons in Japan. The CKD itself is highly risk factor on the cardiac/vascular mortality. In addition,a new concept has been proposed "CKD-MBD". CKD-MBD is composed of a combination of abnormal mineral metabolism, abnormal bone, and extra skeletal calcification with cardiovascular high mortality. Treatment for CKD-MBD is a wide-ranging. We aim to decline cardiovascular event, fracture, and mortality rate of patients with CKD. The main therapeutic target for CKD-MBD becomes the phosphate control. Today, we can use of the VRDA, Calcimimetics and muti-phosphate binders as a lot of pharmacological intervention.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26813506 DOI: CliCa1602259267
Source DB: PubMed Journal: Clin Calcium ISSN: 0917-5857